Results 81 to 90 of about 53,085 (229)
CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib
British Journal of Haematology, EarlyView.Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq +6 more
wiley +1 more source
Scientific ReportsNeuroblastoma (NB) is the most common pediatric tumor and is currently treated by several types of therapies including chemotherapies, such as bortezomib treatment.
Kévin Berthenet +13 more
doaj +1 more source
Haematologica, 2015 We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone ...
Maximilian Merz +22 more
doaj +1 more source
Neoplasia: An International Journal for Oncology Research, 2010 The proteasome inhibitor bortezomib is clinically approved for the treatment of multiple myeloma. However, long-term remissions are difficult to achieve, and myeloma cells often develop secondary resistance to proteasome inhibitors.
Silke Meister +6 more
doaj +1 more source
British Journal of Haematology, EarlyView.Summary Anti‐cluster of differentiation 38 (Anti‐CD38) monoclonal antibodies such as daratumumab are widely used in multiple myeloma (MM), yet the timing and magnitude of infectious risk remain incompletely defined. We performed an individual patient‐level meta‐analysis of six randomized trials (N = 2989) comparing daratumumab‐ versus non‐daratumumab ...
Alissa Visram +7 more
wiley +1 more source
Brain Pathology, EarlyView.Pathogenic JAM2 mutations disrupt the JAM2–JAM3 heterodimer structure and tight junction integrity, leading to blood–brain barrier breakdown. Consequently, Jam2‐deficient mice develop prominent midbrain calcification and significant motor impairments, identifying the JAM2–JAM3 interaction as a vital target for primary brain calcification therapeutics ...
Dehao Yang +24 more
wiley +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
British Journal of Pharmacology, EarlyView.Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka +3 more
wiley +1 more source
Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH‐MM‐15 Study
Cancer Science, EarlyView.t(11;14)‐positive MM is a clinically distinct subgroup characterized by intermediate prognostic risk, modest response depth, and treatment‐dependent outcomes. ABSTRACT t(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor.
Taku Tsukamoto +24 more
wiley +1 more source
The FEBS Journal, EarlyView.Repeated paclitaxel exposure causes long‐lasting nociceptor hyperexcitability and axonal retraction in adult sensory neurons. Using a long‐term primary nociceptor culture, we show that hyperexcitability is mediated by sequential upregulation of NaV1.8, TRPV1, TRPA1, and TRPM8 channels.
Angela Lamberti +3 more
wiley +1 more source